WEST CHESTER, Ohio, Aug. 30 /PRNewswire-FirstCall/ -- AtriCure, Inc. , a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the Thomas Weisel Partners 2007 Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 5th, at 9:45 a.m. ET.
A live Web cast and recording of the presentation will be available on the Investor Relations page of AtriCure’s Web site at www.atricure.com. After the live Web cast, the presentation will remain available on AtriCure’s Web site for 30 days.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices designed to create precise lesions, or scars, in cardiac and soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation clamps as a treatment alternative during open-heart surgical procedures to create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, leading cardiothoracic surgeons have described the AtriCure Isolator(R) bipolar ablation clamps as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 2.5 million Americans and predisposes them to a five-fold increased risk of stroke.
The FDA has cleared the AtriCure Isolator(R) bipolar ablation system for the ablation, or destruction, of cardiac and soft tissues in cardiac and general surgical procedures but has not yet cleared or approved the system for the treatment of AF. The FDA has cleared the AtriCure multifunctional bipolar pen for the ablation of cardiac tissue and for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias, but the multifunctional bipolar pen has not been approved for the treatment of AF.
Contact: AtriCure, Inc. Julie A. Piton Vice President and Chief Financial Officer (513) 755-4561 jpiton@atricure.com
AtriCure, Inc.
CONTACT: Julie A. Piton, Vice President and Chief Financial Officer ofAtriCure, Inc., +1-513-755-4561, jpiton@atricure.com
Web site: http://www.atricure.com/
